Found: 2
Select item for more details and to access through your institution.
A phase III, 52‐week, open‐label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis.
- Published in:
- Journal of Dermatology, 2021, v. 48, n. 8, p. 1149, doi. 10.1111/1346-8138.15927
- By:
- Publication type:
- Article
A phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis.
- Published in:
- Journal of Dermatology, 2021, v. 48, n. 3, p. 279, doi. 10.1111/1346-8138.15668
- By:
- Publication type:
- Article